Aethlon Launches $2.19/Share Offering, Advances Hemopurifier Trials

TL;DR

**AEMD's offering is a high-stakes gamble for a clinical-stage biotech, proceed with extreme caution given the 'best-efforts' structure and potential for significant dilution without guaranteed funding.**

AI Summary

Aethlon Medical, Inc. (AEMD) is conducting a best-efforts offering of up to 4,566,210 shares of common stock and accompanying warrants at a combined public offering price of $2.19 per share. The company is also offering pre-funded warrants for purchasers whose ownership would exceed 4.99% of outstanding common stock, with an exercise price of $0.001 per share. Additionally, 1,550,000 shares of common stock are being offered by selling securityholders upon the exercise of outstanding inducement warrants issued in a private placement on March 16, 2025. AEMD's common stock trades on Nasdaq under 'AEMD', with a last reported sale price of $2.19 per share on August 21, 2025. The company will pay Maxim Group LLC a cash fee of 6.25% of gross proceeds and issue placement agent warrants for 4.0% of the total shares issued in the offering. Aethlon is a 'smaller reporting company' focused on developing the Hemopurifier, a 'Breakthrough Device' for advanced cancer and life-threatening viral infections, with ongoing clinical trials in Australia and planned trials in India. The Data Safety Monitoring Board (DSMB) recommended advancing to the next patient cohort in the Australian oncology trial AEMD-2022-06 on July 15, 2025.

Why It Matters

This offering provides Aethlon Medical with crucial capital to advance its Hemopurifier clinical trials, particularly for its 'Breakthrough Device' designated indications in oncology and viral infections. For investors, the 'best-efforts' nature and lack of a minimum raise introduce significant risk regarding funding adequacy, potentially diluting existing shareholders without securing sufficient capital for long-term operations. Employees and customers could benefit from the continued development of a potentially life-saving therapeutic, but the company's ability to execute on its strategic outlook hinges on the success of this capital raise and subsequent trial outcomes. In the competitive medical device space, securing funding is paramount for clinical-stage companies like Aethlon to progress towards commercialization.

Risk Assessment

Risk Level: high — The offering is a 'best-efforts' offering with no minimum number of shares or aggregate proceeds required, meaning Aethlon Medical may not raise sufficient funds to adequately finance its intended uses of proceeds. This lack of guaranteed funding, coupled with the issuance of up to 4,566,210 shares of common stock and various warrants, presents a high risk of significant dilution for existing shareholders without a clear path to full funding for its clinical programs.

Analyst Insight

Investors should carefully evaluate Aethlon's current cash position and burn rate against the potential proceeds from this 'best-efforts' offering, recognizing that the company may raise substantially less than the maximum. Consider the high dilution risk from the issuance of common stock and warrants, and monitor the progress of the Australian and Indian clinical trials as key catalysts, but be prepared for potential underfunding.

Financial Highlights

debt To Equity

0.0

revenue

$0

operating Margin

N/A

total Assets

$10.3M

total Debt

$0

net Income

$-10.5M

eps

$-0.59

gross Margin

N/A

cash Position

$1.6M

revenue Growth

N/A

Key Numbers

• $2.19 — Combined public offering price per share and accompanying warrant (Fixed price for the duration of the Company Offering)
• 4,566,210 — Maximum shares of common stock and accompanying warrants offered (Represents the total number of securities Aethlon is offering in the Company Offering)
• 1,550,000 — Shares of common stock offered by selling securityholders (Issuable upon exercise of outstanding inducement warrants from a March 16, 2025 private placement)
• 6.25% — Cash fee payable to placement agent (Percentage of aggregate gross proceeds raised at closing of the offering)
• 4.0% — Placement agent warrants (Percentage of total shares of common stock issued in the offering, exercisable by Maxim Group LLC)
• $0.001 — Par value per share of common stock (Also the exercise price for pre-funded warrants)
• 4.99% — Beneficial ownership threshold for pre-funded warrants (Purchasers exceeding this threshold can opt for pre-funded warrants to avoid immediate dilution)
• 9.99% — Increased beneficial ownership threshold (Holders of pre-funded warrants can increase their ownership to this percentage after 61 days notice)
• 164 — Hemopurifier sessions in human studies (Safely utilized across 38 patients, demonstrating potential to remove life-threatening viruses)
• 3 — Participants treated in Australian oncology trial (As of June 26, 2025, in the first of three treatment cohorts for trial AEMD-2022-06)

Key Players & Entities

• AETHLON MEDICAL INC (company) — Registrant and issuer of securities
• Maxim Group LLC (company) — Exclusive placement agent for the offering
• James B. Frakes (person) — Chief Executive Officer of Aethlon Medical, Inc.
• Dennis Doucette, Esq. (person) — Legal counsel from Procopio Cory Hargreaves & Savitch, LLP
• M. Ali Panjwani (person) — Legal counsel from Pryor Cashman LLP
• U.S. Food and Drug Administration (regulator) — Designated Hemopurifier as a 'Breakthrough Device'
• Nasdaq Capital Market (regulator) — Trading market for Aethlon's common stock
• Royal Adelaide Hospital (company) — Hospital conducting clinical trials in Australia
• Pindara Private Hospital (company) — Hospital conducting clinical trials in Australia
• GenesisCare North Shore Hospital (company) — Hospital conducting clinical trials in Australia

FAQ

Risk Factors

• Reliance on Future Financing [high — financial]: The company's ability to continue as a going concern is dependent on its ability to secure additional funding. The S-1/A filing indicates a need for capital to fund operations, research and development, and clinical trials. Failure to obtain necessary financing could lead to a significant curtailment of operations or even bankruptcy.
• Regulatory Approval Uncertainty [high — regulatory]: The development of the Hemopurifier faces significant regulatory hurdles. Obtaining FDA approval, or equivalent approvals in other jurisdictions, is a lengthy and uncertain process. Delays or failure to secure these approvals will prevent commercialization and impact the company's ability to generate revenue.
• Clinical Trial Risks [high — operational]: The company's ongoing and planned clinical trials, such as AEMD-2022-06 in Australia, carry inherent risks. These include patient recruitment challenges, unexpected adverse events, and the possibility that trial results may not demonstrate efficacy or safety. The DSMB's recommendation to advance to the next cohort is positive, but the overall success of the trials remains unproven.
• Market Adoption and Competition [medium — market]: Even if regulatory approval is obtained, the market adoption of the Hemopurifier is not guaranteed. The company will face competition from existing treatments and potentially new entrants in the oncology and virology markets. The novelty of the technology may also require significant market education.
• Dilution from Equity Offerings [medium — financial]: The current offering, which includes up to 4,566,210 shares and accompanying warrants, along with potential shares from selling securityholders, will result in significant dilution for existing shareholders. The company's history of equity raises suggests a continued need for capital, potentially leading to further dilution.
• Manufacturing and Scalability [medium — operational]: Scaling up the manufacturing of the Hemopurifier to meet potential commercial demand presents operational challenges. Ensuring consistent quality and cost-effectiveness at scale will be critical for successful market entry.
• Intellectual Property Protection [medium — legal]: The company's success relies on its intellectual property related to the Hemopurifier. Protecting these patents and proprietary technologies from infringement is crucial. Any legal challenges to their IP could significantly impact the business.
• Limited Operating History and Profitability [high — financial]: Aethlon Medical has a limited operating history and has not achieved profitability. The company's financial performance is heavily reliant on the successful development and commercialization of its lead product candidate, the Hemopurifier.

Industry Context

Aethlon Medical operates in the highly competitive and rapidly evolving biotechnology sector, focusing on novel therapeutic devices for critical unmet medical needs in oncology and infectious diseases. The development of devices like the Hemopurifier requires significant R&D investment and navigating complex regulatory pathways. The industry is characterized by long development cycles, high failure rates, and the potential for substantial rewards if successful treatments are brought to market.

Regulatory Implications

The company's primary regulatory challenge lies in obtaining approval for the Hemopurifier from bodies like the FDA. The 'Breakthrough Device' designation may offer a streamlined pathway, but rigorous clinical evidence of safety and efficacy is still required. Any delays or setbacks in the regulatory process, particularly concerning the Australian and planned Indian trials, pose a significant risk to commercialization.

What Investors Should Do

1. Monitor clinical trial progress and DSMB updates.
2. Assess the company's ability to secure future funding.
3. Evaluate the competitive landscape and market adoption potential.
4. Consider the dilutive impact of ongoing equity raises.

Key Dates

• 2025-07-15: DSMB recommended advancing to the next patient cohort in the Australian oncology trial AEMD-2022-06. — This is a positive development for the Hemopurifier's oncology trial, indicating continued safety and potential efficacy in early-stage patient groups.
• 2025-03-16: Private placement of inducement warrants. — These warrants are now being exercised by selling securityholders, leading to the offering of 1,550,000 shares of common stock.
• 2025-08-21: Last reported sale price of AEMD common stock. — The stock was trading at $2.19, which is the same as the combined public offering price, suggesting the offering price is aligned with current market valuation.

Glossary

Best-efforts offering

An offering where the underwriter is not obligated to purchase any securities from the issuer, but rather will try to sell them on a best-efforts basis. (Indicates that Maxim Group LLC is not guaranteed to sell all the shares offered, potentially impacting the total capital raised by Aethlon.)

Pre-funded warrants

Warrants that allow an investor to purchase shares at a nominal price (here, $0.001) and are immediately exercisable, effectively acting like shares for ownership calculation purposes. (Used to allow investors to exceed the 4.99% ownership threshold without triggering immediate reporting requirements or dilution concerns associated with traditional warrants.)

Breakthrough Device

A designation by the FDA for devices that provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases. (Highlights the potential significance of the Hemopurifier and may expedite the regulatory review process, though it does not guarantee approval.)

Data Safety Monitoring Board (DSMB)

An independent committee of experts responsible for monitoring the safety and efficacy data of clinical trials. (The DSMB's recommendation to advance the oncology trial is a critical milestone, suggesting positive safety and preliminary efficacy signals.)

Inducement warrants

Warrants issued to incentivize a party, often in private placements, to enter into an agreement or transaction. (These warrants, issued in a March 2025 private placement, are now being exercised, leading to the sale of shares by existing securityholders.)

Smaller Reporting Company

A classification by the SEC for companies that meet certain size criteria, allowing them to file less extensive disclosure documents. (Indicates Aethlon is a smaller entity with potentially fewer resources and a higher risk profile compared to larger, more established companies.)

Par value

The nominal value assigned to a share of stock, typically a very small amount. (The par value of $0.001 is also the exercise price for pre-funded warrants, highlighting the minimal cost to acquire these instruments.)

Beneficial ownership threshold

A percentage of a company's outstanding stock that, if owned by an individual or entity, requires them to report their holdings to the SEC. (The 4.99% and 9.99% thresholds are important for investors to manage their reporting obligations and potential dilution.)

Year-Over-Year Comparison

This S-1/A filing represents a significant update from previous filings, primarily detailing a new best-efforts offering of common stock and warrants. While specific comparative financial metrics like revenue and net income are not directly presented in a year-over-year format within this document, the offering itself highlights the company's ongoing need for capital to fund its development pipeline, particularly the Hemopurifier. New risks related to the offering structure, such as dilution and underwriter performance, are now prominent.

Key Financial Figures

• $0.001 — 6,210 shares of common stock, par value $0.001 per share ("common stock"), and accompa
• $2.19 — at a combined public offering price of $2.19 per share of common stock and accompany
• $0 — public in this Company Offering, minus $0.001, and the exercise price of each pre

Filing Documents

• aethlon_s1a1.htm (S-1/A) — 585KB
• aethlonlogo.jpg (GRAPHIC) — 5KB
• aethlon_ex0101.htm (EX-1.1) — 59KB
• aethlon_ex0411.htm (EX-4.11) — 89KB
• aethlon_ex0412.htm (EX-4.12) — 125KB
• aethlon_ex0413.htm (EX-4.13) — 124KB
• aethlon_ex0414.htm (EX-4.14) — 124KB
• aethlon_ex0501.htm (EX-5.1) — 18KB
• aethlon_ex0502.htm (EX-5.2) — 11KB
• aethlon_ex1021.htm (EX-10.21) — 212KB
• aethlon_ex2301.htm (EX-23.1) — 3KB
• aethlon_ex2302.htm (EX-23.2) — 2KB
• image_001.jpg (GRAPHIC) — 4KB
• image_003.jpg (GRAPHIC) — 6KB
• image_002.jpg (GRAPHIC) — 17KB
• image_004.jpg (GRAPHIC) — 5KB
• 0001683168-25-006537.txt ( ) — 1851KB
• aemd-20250829.xsd (EX-101.SCH) — 3KB
• aemd-20250829_lab.xml (EX-101.LAB) — 33KB
• aemd-20250829_pre.xml (EX-101.PRE) — 22KB
• aethlon_s1a1_htm.xml (XML) — 3KB

Risk Factors

Risk Factors 2 1 Special Note Regarding Forward-Looking Statements 25

Use of Proceeds

Use of Proceeds 27 Selling Securityholders 28

Description of Capital Stock

Description of Capital Stock 32

Description of Securities

Description of Securities 34 Certain Material U.S. Federal Tax Consequences 37 Plan of Distribution 41 Legal Matters 4 9 Experts 4 9 Market and Industry Data 4 9 Where You Can Find More Information 4 9 Incorporation of Certain Information by Reference 50 i ABOUT THIS PROSPECTUS You should read this prospectus, including the information incorporated by reference herein. Neither we, the Selling Securityholders nor the placement agent have authorized anyone to provide you with information that is different from that contained in this prospectus or in any free writing prospectus we may authorize to be delivered or made available to you. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. Neither the delivery of this prospectus nor the sale of our securities means that the information contained in this prospectus or any free writing prospectus is correct after the date of this prospectus or such free writing prospectus. This prospectus is not an offer to sell or the solicitation of an offer to buy our securities in any circumstances under which the offer or solicitation is unlawful. The information contained in this prospectus is current only as of the date of this prospectus, regardless of the time of delivery of this prospectus or of any sale of our common stock or warrants. Our business, financial condition, results of operations and prospects may have changed since that date. For investors outside the United this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United of the securities covered hereby and the distr

View Full Filing

View this S-1/A filing on SEC EDGAR